Company intelligence / Profile preview

Cell Genesys

South San Francisco, California, United Statescellgenesys.com ↗

Ownership: Private
Development stage: Other

Overview

Cell Genesys developed novel biological therapies for oncology using its GVAX platform and oncolytic virus technology. Its lead program was a prostate cancer immunotherapy that reached Phase 3 but was ultimately discontinued after clinical trial failures. The company also pursued earlier-stage programs in leukemia, pancreatic cancer, and bladder cancer. After setbacks—including the termination of key partnerships—Cell Genesys merged with BioSante in 2009.

Therapeutic areas: Oncology
Modalities: Cancer vaccineOncolytic virus therapyGene therapyCell therapy
Industry: Biotech

Partnerships

Takeda Pharmaceutical – global marketing/development partnership for prostate-cancer GVAX program; later terminated by mutual agreement after trial failures.Genzyme – acquired manufacturing site from Cell Genesys but not a direct R&D partner.

Beyond the preview

Go deeper on Cell Genesys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell Genesys.